How Long Does Naltrexone Take to Work for Weight Loss?

Naltrexone, when used for weight loss as part of the combination drug naltrexone/bupropion, typically takes four weeks just to reach its full maintenance dose, and most people begin noticing meaningful changes in appetite and eating behavior within that first month. Visible weight loss, though, follows a slower arc. Clinical trials show gradual, sustained loss over roughly a year, with a formal checkpoint at 16 weeks used to judge whether the drug is working well enough to continue. The timeline depends on dosing, individual biology, and what you count as “working.”

The First Few Days and Appetite Effects

Naltrexone starts affecting how food feels almost immediately. In early research, obese men given escalating doses of naltrexone alone over just four consecutive days reduced their food intake at structured meals by about 30%.¹ That is a striking short-term shift, but it did not come from feeling less hungry before the meal. Instead, people ate more slowly, and the food tasted less rewarding as they ate it.² In practical terms, what people sometimes describe as a dulling of food pleasure can start within the first few days of taking naltrexone, even before full doses are reached.

This does not mean the scale moves in those first days. A short-term reduction in how much you eat at any single meal has to accumulate over weeks and months before it translates into measurable weight change. Think of those early appetite shifts as the mechanism switching on, not as weight loss itself.

Why the First Month Is Mostly Ramp-Up

When naltrexone is prescribed for weight management, it almost always comes paired with bupropion in the sustained-release combination known by brand names like Contrave. The prescribing protocol does not start you at the full dose. Instead, medication is initiated at one-quarter of the daily maintenance dose and increased weekly over the first four weeks, reaching the target dose at the beginning of the fourth week.³ This gradual titration exists mainly to manage side effects, particularly nausea, which is the most common reason people stop the medication early.

So during weeks one through three, you are on a sub-therapeutic dose. Some appetite effects can appear during this period, and some weight may come off, but you are not getting the full pharmacological push until roughly week four. Expecting dramatic results before then is setting the wrong benchmark.

How the Combination Actually Works

To understand why the timeline looks the way it does, it helps to know the basic division of labor between the two drugs. Bupropion activates a group of neurons in the brain that suppress appetite. Normally, when those neurons fire, they also release a chemical signal that feeds back and quiets them down, like a built-in off switch. Naltrexone blocks that off switch, so the appetite-suppressing signal stays louder for longer.⁴ Neither drug alone produces large weight loss. Together, they amplify each other’s effect, which is why the combination exists.

Naltrexone’s role in dulling food reward also interacts with individual eating patterns. In a study of obese women, the 50 mg dose of naltrexone specifically blunted food cravings in those who had higher levels of reward-based eating, the kind of eating driven more by pleasure than by hunger. Women who did not eat in a particularly reward-driven way saw less craving reduction.⁵ This is one reason why some people notice a clear change in their relationship with food while others feel like not much is different.

The 16-Week Checkpoint

The most clinically meaningful milestone for judging whether naltrexone/bupropion is “working” comes at 16 weeks. Prescribing guidelines typically recommend assessing whether you have lost at least 5% of your starting body weight by that point. If you have not, the recommendation is usually to discontinue the medication, because the odds of reaching meaningful loss later are relatively low.

This threshold is supported by data. A pooled analysis of large trials found that the 5% loss cutoff at week 16 correctly identified 80% of participants who would or would not go on to achieve at least 5% total weight loss by the end of a full year of treatment.⁶ It is not perfect, though. About 10% of people who had not hit the 5% mark at 16 weeks still ended up there by week 56, meaning they were slow responders who would have been inappropriately pulled off the drug. Another roughly equal group hit 5% at week 16 but then regained some weight and fell below that threshold by the end of the year.⁶

So the 16-week mark is a reasonable but imperfect predictor. If you are losing steadily but have not crossed 5% by exactly that date, it is worth a conversation with your provider rather than an automatic stop.

What the Major Trials Show Over a Full Year

In the COR-I trial, one of the large phase 3 studies, about half of participants taking the higher-dose combination (naltrexone 32 mg plus bupropion) lost at least 5% of their body weight over 56 weeks, compared with about 16% on placebo.⁷ The lower-dose arm, using 16 mg naltrexone, saw about 39% of participants hit that mark. The pattern across trials shows gradual, sustained weight loss that continued over 48 weeks rather than hitting a quick plateau.⁸

The word “gradual” matters here. Unlike GLP-1 receptor agonists, which sometimes produce visible results within the first two weeks, naltrexone/bupropion delivers a slower, steadier trajectory. If you are comparing timelines with friends who started semaglutide or tirzepatide, that difference in speed is real and expected. It does not necessarily mean the medication is failing.

Improvements Beyond the Scale

Eating behavior often shifts before scale weight does. A systematic review of naltrexone’s effects on weight found that improvements in eating symptoms were observed between 4 and 24 weeks.⁹ That is a wide window, but it captures a real pattern: some people feel a rapid change in cravings or binge urges within the first month, while others take several months to notice a meaningful behavioral difference.

In adolescents with eating disorders, naltrexone (used alone, not combined with bupropion) reduced binge eating and purging behaviors in about two-thirds of patients treated, with treatment periods averaging around four months.¹⁰ This was a different clinical population and a different context than standard obesity treatment, but it reinforces the point that naltrexone’s effect on food-related behavior can be a meaningful early signal even when pounds are slow to drop.

Metabolic markers also change on their own timeline. A meta-analysis of trials using bupropion alone or combined with naltrexone found that significant reductions in blood sugar levels became more apparent with treatment lasting longer than 26 weeks, and that insulin levels dropped meaningfully on the same longer timeline.¹¹ Triglycerides, interestingly, improved more with shorter treatment durations around 26 weeks. These metabolic shifts matter because they mean your cardiovascular and metabolic risk profile can improve even before you reach your weight-loss goal.

Nausea and the Early Side-Effect Window

Nausea is the side effect most likely to make you wonder whether the medication is worth continuing, and it tends to hit early. About 9% of people taking naltrexone/bupropion reported nausea during the very first week. After week six, fewer than 1% of patients developed new nausea.¹² When nausea did occur, it was overwhelmingly mild to moderate, with a median duration of about two weeks for mild cases.¹²

This matters for the timeline question because some people lose a few pounds in the first weeks and attribute it to the drug’s appetite effects, when a portion of that early loss may actually be related to eating less because they feel queasy. It is also worth knowing that the nausea itself is not what drives long-term weight loss. The same study found that weight loss in people who experienced nausea and those who did not was independent, meaning the medication’s actual mechanisms were responsible for sustained loss, not just feeling unwell.

If nausea is making the first weeks miserable, the practical advice is to ride it out if it is tolerable, since it almost always resolves within a few weeks. Taking the medication with food and staying hydrated can help. If it is severe enough to interfere with daily life, talk to your prescriber about adjusting the titration speed.

Why Some People Respond Faster Than Others

The variability in how quickly naltrexone seems to “kick in” is something researchers have tried to explain through genetics, eating style, and baseline metabolic status, with limited success so far. One promising hypothesis was that a common genetic variation in the mu-opioid receptor (the protein naltrexone binds to) would predict who responds well. In practice, the evidence for this being a strong predictor has been disappointing. A study that specifically tested whether this genetic variant influenced naltrexone’s effects found little robust evidence that it meaningfully changed outcomes.¹³ That study focused on alcohol-related outcomes rather than eating, but the lack of a clear pharmacogenetic signal has been a consistent theme across naltrexone research.

What does seem to matter is how much of your eating is driven by pleasure and reward rather than physical hunger. As mentioned earlier, people with stronger reward-driven eating patterns tend to get more craving relief from naltrexone, which can translate into earlier behavioral changes and potentially faster weight loss. There is no simple test for this, but if you find that your eating is more about emotional comfort or intense food cravings than about hunger signals, naltrexone’s mechanism may align well with your particular biology.

What Happens When You Stop

The weight-loss timeline has a second half that many people do not think about until they are already considering discontinuation. A large systematic review and meta-analysis published in 2025 found that, across weight-management medications in general, the average rate of weight regain after stopping was roughly 0.4 kilograms per month. All cardiometabolic markers were projected to return to their pre-treatment baseline within about a year and a half after stopping the medication.¹⁴ Weight regain was also faster after stopping medication than after stopping a structured behavioral weight-management program, independent of how much weight had been lost initially.¹⁴

This is not unique to naltrexone/bupropion. It reflects a broader reality of pharmacological weight management: the drugs alter appetite and metabolism while you are taking them, but those effects do not persist once the drug clears your system. If you are thinking of naltrexone/bupropion as a time-limited intervention that will reset your weight permanently, the data suggest that is not how it works for most people. Some weight can be maintained through lifestyle changes made during treatment, but the pharmacological contribution reverses.

Naltrexone Alone Versus the Combination

Most of the clinical trial data on weight loss involves naltrexone combined with bupropion, because that is the formulation that went through formal obesity trials and received regulatory approval. Naltrexone alone, at the standard 50 mg dose used for alcohol or opioid dependence, has weaker evidence for weight loss. The early studies showing 30% reductions in meal intake used naltrexone by itself, but those were short-term feeding experiments, not long-term weight outcomes.¹

Some providers do prescribe naltrexone on its own off-label for weight management, sometimes at lower doses. The evidence base for this is thinner and the expected timeline is less well defined. If you are taking naltrexone alone rather than the branded combination, the appetite effects may still be present but the magnitude of weight loss is likely to be smaller, and there is no clear 16-week decision threshold established for that use.

Low-Dose Naltrexone and Weight

Low-dose naltrexone, typically in the range of 1 to 5 mg, has developed a following for various off-label uses including chronic pain, autoimmune conditions, and sometimes weight management. This is a very different pharmacological situation than the standard dosing used in clinical trials. At low doses, naltrexone briefly blocks opioid receptors and then clears, which is theorized to cause a temporary rebound increase in endorphin production. Whether this translates into meaningful weight loss has not been established in large trials. The timeline question for low-dose naltrexone and weight loss essentially has no evidence-based answer right now. If someone is prescribing it for this purpose, the expected timeline is speculative.

Realistic Expectations by Week

Pulling together the evidence, here is a rough sketch of what to expect at each stage:

• Weeks 1 to 4: You are ramping up to the full dose. Some appetite changes may appear, especially reduced food pleasure and slower eating. Nausea is most likely during this period but usually resolves. Weight change is minimal for most people.
• Weeks 4 to 8: The full dose is on board. Appetite suppression and craving reduction become more consistent. A few pounds of loss may start appearing, though the pace varies widely.
• Weeks 8 to 16: This is the window where the medication’s weight-loss effect becomes measurable. If the drug is going to work well for you, you should be seeing a clear downward trend by the end of this period.
• Week 16: The clinical checkpoint. Losing at least 5% of starting weight by now correctly predicts long-term success about 80% of the time. If you have not reached that threshold, the odds of catching up later are lower but not zero.
• Months 5 to 12: Continued gradual loss for responders. Metabolic improvements in blood sugar and insulin levels become more pronounced after about 26 weeks. The trajectory is slow and steady rather than dramatic.

The honest framing is that naltrexone/bupropion is a slow-burn medication. It takes a month to reach full dosing, four months to know whether it is working, and nearly a year to see its full potential. For people accustomed to the rapid, visible results now associated with newer injectable weight-loss drugs, this timeline can feel frustratingly slow. But the combination still produces clinically significant weight loss in a substantial fraction of users, and it remains one of the few oral options available for long-term weight management.